Reversal agents for current and forthcoming direct oral anticoagulants

Area of Science:

• Pharmacology
• Cardiology
• Hematology

Background:

• Shift from vitamin K antagonists to direct oral anticoagulants (DOACs) over the past 20 years.
• DOACs, including dabigatran and factor Xa inhibitors (apixaban, edoxaban, rivaroxaban), are associated with less bleeding than vitamin K antagonists.
• Bleeding events with DOACs, particularly in elderly patients and those with comorbidities, necessitate effective reversal strategies.

Purpose of the Study:

• To provide an updated guide on the indications and methods for reversing DOACs.
• To review novel reversal agents currently under development.
• To propose a strategic framework for reversing factor XI inhibitors in clinical trials.

Main Methods:

• Review of current literature on DOAC reversal.
• Description of available specific and non-specific reversal agents.
• Discussion of emerging reversal therapies and future directions.

Main Results:

• Specific reversal agents (idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors) are available.
• Non-specific agents like prothrombin complex concentrates can also be used.
• New reversal agents are under investigation for DOACs and factor XI inhibitors.

Conclusions:

• Effective reversal of DOACs is crucial in managing bleeding complications and urgent procedures.
• The development of new reversal agents promises improved patient outcomes.
• A strategic approach is needed for the management of bleeding associated with both current and emerging anticoagulants.